"这个势头是可持续的，并不会迅速开始下降。" 2026年，中国新药出海热度不减。 1月尚未结束，中国药企已经完成10笔海外授权交易，其中荣昌生物和艾伯维的交易首付款达到6.5亿美元。 2025年是中国创新药海外交易的大年。第一财经采访的医药和投资机构人士均认为，这种趋势会延续下去。摩根大通大中华区医疗健康行业研究主管黄旸表 示："2026年出海交易数量或者总金额可能难以超过2025年，但会维持强劲的势头。" 首付款超过一级市场融资 最近两年，代谢领域的授权交易升温。2025年，中国药企发生了七笔对外授权。这很大程度上源于礼来和诺和诺德在减重药物市场取得的令人瞩目的成功。 礼来更是成为全球首家市值突破一万亿美元的医药公司，与英伟达、苹果、谷歌等科技巨头并肩而立。 中国代谢领域的交易，是2025年创新药海外授权爆发性增长的缩影。 据医药魔方统计，2025年中国新药对外授权交易158笔，总交易金额1357亿美元，交易数量和金额都达到十年新高。 事实上，2023年和2024年，中国创新药海外授权交易的数量和交易额已经连续突破纪录。医药研发是厚积薄发的过程，即便是临床一期药物，也可能已经经 历了五年左右的研发。2025 ...

Core Viewpoint - The innovative drug sector is experiencing fluctuations and adjustments, but the rise of AI drug development technologies is injecting new vitality into the industry, enhancing research efficiency and reducing costs, which is expected to bolster the sector's growth [1][4]. Group 1: Market Activity - Over 100 billion yuan has flowed into innovative drug-themed ETFs since August, with significant net subscriptions recorded, including 42.36 billion yuan for the Huatai-PineBridge Hong Kong Innovative Drug ETF and 40.93 billion yuan for the GF Hong Kong Innovative Drug ETF [2]. - On August 19, despite a drop of over 3% in several innovative drug ETFs, more than 30 billion yuan was still invested, indicating strong market interest [2]. - Several ETFs have reached record high shares since their inception, with the Huatai-PineBridge Hong Kong Innovative Drug ETF reaching 8.338 billion shares [2]. Group 2: Fund Management Actions - Multiple actively managed funds heavily invested in the innovative drug sector have restricted large subscriptions, such as the Changcheng Medical Industry Selected Mixed Fund limiting purchases to 1 million yuan [3]. - The Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund has also suspended subscriptions, reflecting a cautious approach amid market volatility [3]. Group 3: Institutional Insights - Fund managers believe that the innovative drug sector has significant long-term growth potential, driven by advancements in AI and ongoing policy support, which could position Chinese innovative drug companies more prominently in the global market [4][5]. - The profitability of leading innovative drug companies is improving, supported by a large domestic market and the potential for Chinese innovative drugs to capture 30% to 50% of the global market share, translating to a profit scale of 20 billion to 30 billion USD [5]. - The innovative drug sector is expected to continue its upward trajectory, with a focus on companies with strong fundamentals, while remaining vigilant about potential risks associated with market-driven stocks [5].

Group 1 - The overall investment in the pharmaceutical industry has not recovered despite positive news regarding innovative drugs, with 61 companies forecasting profits and 46 forecasting losses as of July 30, 2025 [1] - Pharmaceutical outsourcing service companies (CROs) have reported better-than-expected performance, with WuXi AppTec's revenue for the first half of 2025 reaching 20.64% growth year-on-year, and net profit increasing by 101.92% [3] - The CRO sector has seen a significant recovery in orders and performance, with over 50 global cooperation agreements in innovative drugs totaling over $48.4 billion in the first half of 2025 [4] Group 2 - 20 companies have reported their first net profit losses, with major contributors including Liao Ning Cheng Da and Wan Tai Bio, primarily due to policy impacts and market strategy failures [6] - Wan Tai Bio reported a projected net loss of between 130 million to 160 million yuan for the first half of 2025, marking its first loss since going public in 2020 [6][7] - Jiangsu Lianhuan Pharmaceutical expects a net loss of 38 million to 45 million yuan for the first half of 2025, attributed to a significant fine related to a monopoly agreement [7][8] Group 3 - The trend of business development (BD) in innovative drugs is expected to continue, with the total transaction amount approaching last year's levels, although the quality of these transactions may decline [10] - The vaccine and CXO sectors are anticipated to see a turnaround in the second half of 2025, with domestic vaccines expected to gain market share [10] - New opportunities may arise in technology platforms, with ADC and bispecific antibodies being key transaction categories, while multi-antibody platforms and TCE platforms are expected to gain traction [10]

Group 1 - The Hong Kong Innovation Drug ETF (513120) has seen a strong increase of 3.37%, marking a four-day consecutive rise, with significant gains in constituent stocks such as Green Leaf Pharmaceutical (02186) up 8.50% and WuXi AppTec (02359) up 7.97% [1] - The ETF's trading volume was active, with a turnover of 31.99% and a total transaction value of 4.947 billion [1] - The ETF's latest scale reached 15.136 billion, a new high in nearly a year, ranking first among Hong Kong pharmaceutical ETFs [1] Group 2 - The CSI Hong Kong Innovation Drug Index (931787) closely tracks the performance of up to 50 listed companies involved in innovative drug research and development, with a significant weight of 92.5% in biopharmaceuticals and chemical pharmaceuticals [2] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 67.94%, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [2] - WuXi AppTec reported a revenue of 20.799 billion, a year-on-year increase of 20.64%, with net profit rising by 101.92% to 8.56 billion [2] Group 3 - Heng Rui Medicine announced a licensing agreement with GSK for the global exclusive rights to the HRS-9821 project, receiving an upfront payment of 500 million and potential total payments of approximately 12 billion [3] - The total amount of overseas licensing transactions for innovative drugs in China increased by 26% in 2024, with over 2.5 billion in upfront payments in the first half of 2025 [3] - The Hong Kong Innovation Drug ETF supports T+0 trading, enhancing liquidity and capital efficiency for investors [3]

Group 1 - The core viewpoint of the article is the release of measures by the National Healthcare Security Administration and the National Health Commission to promote the global market development of innovative drugs [1][2] - The measures emphasize leveraging China's vast production capacity, large market, and rich experience to actively promote the achievements of Chinese innovative drug development in international cooperation [1] - The document encourages regions with conditions to explore building global innovative drug trading platforms targeting Southeast Asia, Central Asia, and other Belt and Road countries, enhancing international promotion [1] Group 2 - In 2024, Chinese pharmaceutical companies completed over 90 overseas licensing transactions, totaling more than $50 billion [1] - The measures highlight three basic considerations: building platforms to assist in expanding overseas markets, supporting innovative enterprises' rapid development, and providing price support for innovative drugs going abroad [2] - The National Healthcare Security Administration plans to adopt a price confidentiality mechanism for innovative drugs, especially for those in commercial insurance directories, to facilitate their overseas listing [2]